Fate Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Details
| Name | Fate Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 161 |
| Founded | 2007 |
| Ipo Date | 2013-10-01 |
| Ceo | Bahram Valamehr |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US31189P1021 |
| Cusip | 31189P102 |
| Cik | 0001434316 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Kamal Adawi M.S., MBA | Chief Financial Officer and Treasurer |
| Cindy R. Tahl J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Jessica Francis | Senior Vice President of Human Resources and Operations |
| Dr. Martin Hosking | Head of Research |
| Dr. Tunde Babalola Ph.D. | Senior Vice President of Technical Operations and Quality |
| Ryan Douglas | Senior Director of Investor Relations and Business Development |
| Andrew Henry | Senior Vice President of Clinical Operations |
| Dr. Yu Cai J.D., Ph.D. | Head of Intellectual Property and Assistant General Counsel |
Contact
| Address | 12278 Scripps Summit Drive, San Diego, California 92131, United States |
| Phone | 858 875 1800 |
| Website | https://www.fatetherapeutics.com |